The role of interventional therapies in cancer pain management

Annals of the Academy of Medicine Singapore

Volumn 38, Issue 11, 2009, Pages 989-997

  Tay, Wilson ^a   Ho, Kok Yuen ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

Intractable pain; Intrathecal analgesia; Neurolysis

Indexed keywords

ALCOHOL; BUPIVACAINE; CLONIDINE; HYDROMORPHONE; MORPHINE; OMEGA CONOTOXIN MVIIA; PHENOL; POLY(METHYL METHACRYLATE);

ADJUVANT THERAPY; ADRENERGIC RECEPTOR BLOCKING; ANESTHESIA COMPLICATION; ANESTHESIA MECHANISM; ANOREXIA; AUTONOMIC DYSFUNCTION; BLADDER DYSFUNCTION; BODY WEIGHT; BRADYCARDIA; CANCER PAIN; CATHETER INFECTION; CATHETER OCCLUSION; CELIAC PLEXUS; CHRONIC PAIN; CONFUSION; CONSTIPATION; CONTINUOUS EPIDURAL ANESTHESIA; CONTINUOUS INFUSION; CORDOTOMY; DEPRESSION; DIARRHEA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; EDEMA; FATIGUE; GAIT DISORDER; GRANULOMA; HEADACHE; HUMAN; HYGROMA; HYPERALGESIA; HYPERTENSION; HYPOGASTRIC PLEXUS; INSOMNIA; INTRATHECAL NEUROLYSIS; KYPHOPLASTY; LETHARGY; LIBIDO DISORDER; LIMB WEAKNESS; MENINGITIS; MOTOR DYSFUNCTION; MYOCLONUS SEIZURE; NAUSEA; NERVE BLOCK; NEUROLYSIS; NEUROPATHIC PAIN; NEUROTOXICITY; NIGHTMARE; NYSTAGMUS; ORTHOSTATIC HYPOTENSION; PARAPLEGIA; PARESTHESIA; PATIENT ASSESSMENT; PERCUTANEOUS VERTEBROPLASTY; PNEUMOTHORAX; POSTDURAL PUNCTURE HEADACHE; PRACTICE GUIDELINE; PRURITUS; PSYCHOSIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; RETROPERITONEAL HEMATOMA; REVIEW; RHABDOMYOLYSIS; SEDATION; SENSORY DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SUICIDE; SWEATING; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT RESPONSE; URINE RETENTION; VOMITING; WEAKNESS; XEROSTOMIA;

EID: 73249126041     PISSN: 03044602     EISSN: 29724066     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. World Health Organization. World Cancer Report - International Agency for Research on Cancer. In: Stewart BW, Kleihues P, editors. Geneva, Switzerland: WHO, 2003.
2. Higginson IJ. Innovations in assessment: epidemiology and assessment of pain in advanced cancer. In: Jensen TS, Turner JA, Wiesenfeld-Hallin Z, editors. Proceedings of the 8th World Congress on Pain: Progress in Pain Research and Management. Seattle (WA): IASP Press, 1997.
3. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. Pain 1999;82:263-74.
4. Grond S, Zech D, Diefenbach C, Radbruch L, Lehmann KA. Assessment of cancer pain: a prospective evaluation of 2266 cancer patients referred to a pain service. Pain 1996;64:107-14.
5. Portenoy RK, Lesage P. Management of cancer pain. Lancet 1999;353:1695-700.
6. Grond S, Zech D, Schug SA, Lynch J, Lehmann KA. Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 1991;6:411-22.
7. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 1995;63:65-76.
8. Walker VA, Hoskin PJ, Hanks GW, White ID. Evaluation of WHO analgesic guidelines for cancer pain in a hospital-based palliative care unit. J Pain Symptom Manage 1988;3:145-9.
9. Fallon M, Hanks G, Cherny N. Principles of control of cancer pain. BMJ 2006;332:1022-4.
10. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330:592-6.
11. Enting RH, Oldenmenger WH, van der Rijt CC, Wilms EB, Elfrink EJ, Elswijk I, et al. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Cancer 2002;94:3049-56.
12. World Health Organization (WHO), WHO expert committee on cancer pain relief and active supportive care. Cancer pain relief and palliative care: Report of a WHO expert committee. 3rd ed. Geneva: WHO, 1996.
13. Miguel R. Interventional treatment of cancer pain: the fourth step in the WHO analgesic ladder? Cancer Control 2000;7:149-56.
14. Erdine S. Interventional treatment of cancer pain. Eur J Cancer Suppl 2005;3:97-106.
15. Manchikanti L, Fellows B, Singh V. Understanding psychological aspects of chronic pain in interventional pain management. Pain Physician 2002;5:57-82.
16. Bender JL, Hohenadel J, Wong J, Katz J, Ferris LE, Shobbrook C, et al. What patients with cancer want to know about pain: A qualitative study. J Pain Symptom Manage 2008;35:177-87.
17. Plancarte R, Alvarez J, Arrieta MC. Interventional treatment of cancer pain. Semin Pain Med 2003;1:34-42
18. Eisenberg E, Carr DB, Chalmers TC. Neurolytic coeliac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg 1995;80:290-5
19. Pert CB, Synder SH. Opioid receptor: demonstration in nervous tissue. Science 1973;179:1947-9.
20. Behar M, Magora F, Olshwang D, Davidson JT. Epidural morphine in treatment of pain. Lancet 1979;1:527-9.
21. Wang JK, Nauss LA, Thomas JE. Pain relief by intrathecally applied morphine in man. Anesthesiology 1979;50:149-51.
22. Hanks GW, Coon F, Cherny N, Hanna M, Kalso E, McQuay HJ, et al; Expert Working Group of the Research Network of the European Association of Palliative Care. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-93.
23. Comparative efficacy of epidural, subarachnoid and intracerebroventricular opioids in patients with pain due to cancer. The Cochrane Database of Systematic Reviews. 2006, Issue 1, art no. CD 005178.
24. Smith TJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, et al. Implantable drug delivery systems study group. Randomised clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain; impact on pain, drugrelated toxicity, and survival. J Clin Oncol 2002;20:4040-9.
25. Chambers WA. Nerve blocks in palliative care. Br J Anaesth 2008; 101:95-100.
26. Staats P. Neuraxial infusion for pain control. Oncology 1999;13:58-62.
27. Krames ES, Lanning RM. Intrathecal infusional analgesia for nonmalignant pain: analgesic efficacy of intrathecal opioid with or without bupivacaine. J Pain Symptom Manage 1993;8:539-48.
28. Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain 1995;61:391-9.
29. Kedlaya D, Reynolds L, Waldman S. Epidural and intrathecal analgesia for cancer pain. Best Pract Res Clin Anaesthesiol 2002;16:651-5.
30. Dahm P, Nitescu P, Applegren L, Curelaru I. Efficacy and technical complications of long-term continuous intraspinal infusions of opioid and/ or bupivacaine in refractory non malignant pain; a comparison between the epidural and intrathecal approach with externalized or implanted catheters and infusion pumps. Clin J Pain 1998;14:4-16.
31. Baker L, Lee M, Regnard C. Evolving spinal analgesia practice in palliative care. Palliat Med 2004;18:507-15.
32. Gestin Y, Vainio A, Pergurier AM. Long-term intrathecal infusion of morphine in the home care of patients with advanced cancer. Acta Anaesthesiol Scand 1997;41:12-7.
33. Sjoberg M, Karlsson PA, Nordborg C, Wallgren A, Nitescu P, Appelgren L, et al. Neuropathologic findings after long-term intrathecal infusion of morphine and bupivicaine for pain treatment in cancer patients. Anaesthesiology 1992;76:173-86.
34. Penn RD, Paice JA, Gottschalk W, Ivankovic AD. Cancer pain relief using chronic morphine infusion. Early experience with a programmable implanted drug pump. Neurosurgery 1984;61:302-6.
35. Classen AM, Wimbish GH, Kupiec TC. Stability of admixture containing morphine sulfate, bupivacaine hydrochloride, and clonidine hydrochloride in an implantable infusion system. J Pain Symptom Manage 2004;28:603-11.
36. Devulder J, Ghys L, Dhondt W, Roily G. Spinal analgesia in terminal care: risk versus benefit. J Pain Symptom Manage 1994;9:75-81.
37. Mercadante S. Problems of long-term spinal opioid treatment in advanced cancer patients. Pain 1999;79:1-13.
38. Rigler ML, Drasner K, Krejcie TC, Yelich SJ, Scholnick FT, DeFontes J, et al. Cauda equina syndrome after continuous spinal anesthesia. Anesth Analg 1991;72:275-81.
39. North RB, Cutchis PN, Epstein JA, Long DM. Spinal cord compression complicating subarachnoid infusion of morphine: Case report and laboratory experience. Neurosurgery 1991;29:778-84.
40. Yaksh TL, Hassenbusch S, Burchiel K, Hildebrand KR, Page LM, Coffey RJ. Infl ammatory masses associated with intrathecal drug infusion: A review of preclinical evidence and human data. Pain Med 2002;3:300-12.
41. Deer TR. A prospective analysis of intrathecal granuloma in chronic pain patients: A review of the literature and report of a surveillance study. Pain Physician 2004;7:225-8.
42. Applegren L, Nordborg C, Sjoberg M, Karlsson PA, Nitescu P, Curelaru I. Spinal epidural metastasis: implications for spinal analgesia to treat 'refractory' cancer pain. J Pain Symptom Manage 1997;13:25-42.
43. Mueller-Schwefe G, Hassenbusch SJ, Reig E. Cost effectiveness of intrathecal therapy for pain. Neuromodulation 1999;2:77-87.
44. Southall JL, Beddall C, Raphael JH. Cost utility analysis of intrathecal pump implant for chronic nonmalignant low back pain. Neuromodulation 2006;9:156-7.
45. Bedder MD, Burchiel K, Larson A. Cost analysis of two implantable narcotic delivery systems. J Pain Symptom Manage 1991;6:368-73.
46. Rauck RL, Cherry D, Boyer MF, Kosek P, Dunn J, Alo K. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain 2003;4:441-7.
47. Kumar K, Kelly M, Pirlot T. Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: Long-term benefits and efficacy. Surg Neurol 2001;55:79-86.
48. Scherens A, Kagel T, Zenz M, Maier C. Long-term respiratory depression induced by intrathecal morphine treatment for chronic neuropathic pain. Anesthesiology 2006;105:431-3.
49. Ruan X. Drug-related side effects of long-term intrathecal morphine therapy: A focused review. Pain Physician 2007;10:357-366.
50. Anderson VC, Cooke B, Burchiel KJ. Intrathecal hydromorphone for chronic nonmalignant pain: A retrospective study. Pain Med 2001;2:287-97.
51. Coffey RJ, Burchiel K. Infl ammatory mass lesions associated with intrathecal drug infusion catheters: Report and observations on 41 patients. Neurosurgery 2002;50:78-86.
52. Deer T, Krames ES, Hassenbusch SJ, Burton A, Caraway D, Dupen S, et al. Polyanalgesic Consensus Conference 2007: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel. Neuromodulation 2007;10:300-28.
53. Akerman B, Arwestrom E, Post C. Local anaesthetics potentiate spinal morphine antinociception. Anesth Analg 1988;67:943-8.
54. van Dongen RT, Crul BJ, van Egmond J. Intrathecal coadministration of bupivacaine diminishes morphine dose progression during long-term intrathecal infusion in cancer patients. Clin J Pain 1999;15:166-72.
55. Mironer EY, Haasis JC, Chapple I, Brown C, Satterthwaite JR. Efficacy and safety of intrathecal opioid/bupivacaine mixture in chronic nonmalignant pain: A double blind, randomized, crossover, multicenter study by the National Forum of Independent Pain Clinicians (NFIPC). Neuromodulation 2002;5:208-13.
56. Coombs DW, Saunders RL, Lachance D, Savage S, Ragnarsson TS, Jensen LE. Intrathecal morphine tolerance: use of intrathecal clonidine, DADLE, and intraventricular morphine. Anesthesiology 1985;62:358-63.
57. Coombs DW, Saunders RL, Fratkin JD, Jenson LE, Murphy CA. Continuous intrathecal hydromorphone and clonidine for intractable cancer pain. J Neurosurg 1986;64:890-4.
58. Bevacqua BK, Fattouh M, Backonja M. Depression, night terrors, and insomnia associated with long-term intrathecal clonidine therapy. Pain Practice 2007;7:36-8.
59. Fitzgibbon D, Rapp S, Butler S, Terman G, Dolack G, Dupen S, et al. Rebound hypertension and withdrawal associated with discontinuation of an infusion of epidural clonidine. Anesthesiology 1996;84:729-31.
60. Olivera BM, Cruz LJ, de Santos V, LeCheminant GW, Griffin D, Zeikus R, et al. Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom. Biochemistry 1987;26:2086-90.
61. Staats PS, Yearwood T, Charapata SG, Presley RW, Wallace MS, Byas-Smith M, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA 2004;291:63-70.
62. Rauck RL, Wallace MS, Leong MS, Minehart M, Webster LR, Charapata SG, et al; Ziconotide 301 Study Group. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage 2006;31:393-406.
63. Shields D, Montenegro R, Ragusa M. Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration. Neuromodulation 2005;8:257-63.
64. Shields D, Montenegro R. Chemical stability of ziconotide-clonidine hydrochloride admixtures with and without morphine sulfate during simulated intrathecal administration. Neuromodulation 2007;10[suppl 1]:6-11.
65. Candido K, Stevens R. Intrathecal neurolytic blocks for the relief of cancer pain. Best Pract Res Clin Anaesthesiol 2003;17:407-28.
66. Gerbershagen HU. Neurolysis. Subarachnoid neurolytic blockade. Acta Anaesthesiol Belg 1981;32:45-57.
67. Ischia S, Ischia A, Polati E, Finco G. Three posterior percutaneous coeliac plexus block techniques: a prospective randomized study in 61 patients with pancreatic cancer pain. Anesthesiology 1992;76:534-40.
68. Mercadante S. Coeliac plexus block versus analgesics in pancreatic cancer pain. Pain 1993;52:187-92.
69. Wong G, Schroeder DR, Carns PE, Wilson JL, Martin DP, Kinney MO, et al. Effect of neurolytic coeliac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a randomized controlled trial. JAMA 2004;291:1092-9.
70. De Cicco M, Matovic M, Bortolussi R, Coran F, Fantin D, Fabiani F, et al. Coeliac plexus block: injectate spread and pain relief in patients with regional anatomic distortions. Anesthesiology 2001;94:561-5.
71. Eisenberg E, Carr DB, Chalmers TC. Neurolytic coeliac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg 1995;80:290-5.
72. Hayakawa J, Kobayashi O, Murayama H. Paraplegia after intraoperative coeliac plexus block. Anesth Analg 1997;84:447-8.
73. Wong GY, Brown DL. Transient paraplegia following alcohol coeliac plexus block. Reg Anesth 1995;20:352-5.
74. Teng J. Cancer pain and neurolysis. Semin Anesth 2003;22:175-85.
75. de Leon-Casasola OA. Critical evaluation of chemical neurolysis of the sympathetic axis for cancer pain. Cancer Control 2000;7:142-8.
76. Plancarte R, Amescua C, Patt RB, Aldrete JA. Superior hypogastric plexus block for pelvic cancer pain. Anesthesiology 1990;73:236-9.
77. de Leon-Casasola OA, Kent E, Lema MJ. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Pain 1993;54:145-51.
78. Plancarte R, de Leon-Casasola OA, El-Helaly M, Allende S, Lema MJ. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Reg Anesth 1997;22:562-8.
79. Nebab EG, Florence IM. An alternative needle geometry for interruption of the ganglion impar. Anesthesiology 1997;86:1213-4.
80. Munir MA, Zhang J, Ahmad M. A modified needle-inside-needle technique for the ganglion impar block. Can J Anaesth 2004;51:915-7.
81. Foye PM. New approaches to ganglion impar blocks via coccygeal joints. Reg Anesth Pain Med 2007;32:269.
82. Ho KY, Nagi PA, Gray L, Huh BK. An alternative approach to ganglion impar neurolysis under computed tomography guidance for recurrent vulva cancer. Anesthesiology 2006;105:861-2.
83. Gupta D, Jain R, Mishra S, Kumar S, Thulkar S, Bhatnagar S. Ultrasonography reinvents the originally described technique for ganglion impar neurolysis in perianal cancer pain. Anesth Analg 2008;107:1390-2.
84. Khor KE, Ditton JN. Femoral nerve blockade in the multidisciplinary management of intractable localized pain due to metastatic tumor: a case report. J Pain Symptom Manage 1996;11:57-61.
85. Fischer HB, Peters TM, Fleming IM, Else TA. Peripheral nerve catheterization in the management of terminal cancer pain. Reg Anesth 1996;21:482-5.
86. Vranken JH, Zuurmond WW, de Lange JJ. Continuous brachial plexus block as treatment for the Pancoast Syndrome. Clin J Pain 2000;16:327-33.
87. Mercadante S, Sapio M, Vilari P. Suprascapular nerve block by catheter for breakthrough shoulder cancer pain. Reg Anesth 1995;20:343-6.
88. Calava JM, Patt RB, Reddy S, Varma DG, Chiang J. Psoas sheath chemical neurolysis for management of intractable leg pain from metastatic liposarcoma. Clin J Pain 1996;12:69-75.
89. Kaki AM, Lewis GW. Inguinal paravascular (lumbar plexus) neurolytic block - description of a catheter technique: case report. Reg Anesth Pain Med 1998;23:214-8.
90. Antila H, Kirvela O. Neurolytic thoracic paravertebral block in cancer pain. A clinical report. Acta Anaesthesiol Scand 1998;42:581-5.
91. Fineman SP. Long-term post-thoracotomy cancer pain management with interpleural bupivacaine. Anesth Analg 1989;68:694-7.
92. Myers DP, Lema MJ, de Leon-Casasola OA, Bacon DR. Interpleural analgesia for the treatment of severe cancer pain in terminally ill patients. J Pain Symptom Manage 1993;8:505-10.
93. Dravid RM, Paul RE. Interpleural block - part 1. Anaesthesia 2007; 62:1039-49.
94. Giller CA. The neurosurgical treatment of pain. Arch Neurol 2003;60:1537-40.
95. Sanders M, Zuurmond W. Safety of unilateral and bilateral percutaneous cervical cordotomy in 80 terminally ill cancer patients. J Clin Oncol 1995;13:1509-12.
96. Wong ET, Gunes S, Gaughan E, Patt RB, Ginsberg LE, Hassenbusch S, et al. Palliation of intractable cancer pain by MRI-guided cingulotomy. Clin J Pain 1997;13:260-3.
97. Burton AW, Mendel E. Vertebroplasty and kyphoplasty. Pain Physician 2003;6:335-41.